SCHEMBL3604299

SCHEMBL3604299

CN(CCNC(=O)Cn1ccc2ccc(-c3ccccc3C(N)=O)cc21)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTSR1 P30989 2/20 0.41
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 2/20 0.40
CYP3A4 P08684 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TSHR P16473 5/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 5/20 0.39
USP2 O75604 1/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
CCKAR P32238 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3593044 0.90 NTSR1 (0.42) NTSR1ALDH1A1KDM4EHPGDLMNA
SCHEMBL3601863 0.89 GRIN2B (0.45) NTSR1ALDH1A1KDM4EHPGDLMNA
SCHEMBL3598446 0.87 KDM4E (0.44) NTSR1ALDH1A1KDM4EHPGDLMNA
SCHEMBL3600541 0.86 KDM4E (0.46) ALDH1A1KDM4EHPGDLMNACYP3A4
SCHEMBL3603616 0.86 KDM4E (0.42) NTSR1ALDH1A1KDM4EHPGDLMNA
SCHEMBL3601363 0.84 KDM4E (0.43) ALDH1A1KDM4EHPGDLMNACYP3A4
SCHEMBL3600058 0.84 KDM4E (0.41) NTSR1ALDH1A1KDM4EHPGDLMNA
SCHEMBL14396650 0.84 KDM4E (0.42) NTSR1ALDH1A1KDM4EHPGDLMNA
SCHEMBL3604301 0.84 ALDH1A1 (0.40) NTSR1ALDH1A1KDM4EHPGDLMNA
SCHEMBL3602466 0.83 KDM4E (0.44) ALDH1A1KDM4EHPGDLMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 NTSR1 1072/4885ALDH1A1 662/4885KDM4E 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.